We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An Australian appeals court has supported Myriad Genetics’ ability to patent genes associated with breast-cancer risk, diverging from last year’s U.S. Supreme Court ruling, which declared the patents invalid. Read More